title: Maternal DDAVP-induced hyponatremia preserves fetal urine flow during acute fetal hemorrhage.
abstract: Maternal administration of DDAVP induces maternal and fetal plasma hyponatremia, accentuates fetal urine flow, and increases amniotic fluid volume. Fetal hemorrhage represents an acute stress that results in fetal AVP secretion and reduced urine flow rate. In view of the potential therapeutic use of DDAVP for pregnancies with reduced amniotic fluid volume, we sought to examine the impact of maternal hypotonicity during acute fetal hemorrhage. Chronically catheterized pregnant ewes (130 +/- 2 days) were allocated to control or to DDAVP-induced hyponatremia groups. In the latter group, tap water (2,000 ml) was administered intragastrically to the ewe followed by DDAVP (20 microg bolus, 4 microg/h) and a maintenance intravenous infusion of 5% dextrose water for 4 h to achieve maternal hyponatremia of 10-12 meq/l. Thereafter, ovine fetuses from both groups were continuously hemorrhaged to 30% of estimated blood volume over a 60-min period. DDAVP caused similar degree of reductions in plasma sodium and osmolality in pregnant ewes and their fetuses. In response to hemorrhage, DDAVP fetuses showed greater reduction in hematocrit than control fetuses (14 vs. 10%). Both groups of fetuses demonstrated similar increases in plasma AVP concentration. However, the AVP-hemorrhage threshold was greater in DDAVP fetuses (22.5%) than in control (17.5%). Hemorrhage had no significant impact on plasma osmolality, electrolyte levels, or cardiovascular responses in either group of fetuses. Despite similar increases in plasma AVP, DDAVP fetuses preserved fetal urine flow rates, with values threefold those of control fetuses. These results suggest that under conditions of acute fetal stress of hemorrhage, maternal DDAVP may preserve fetal urine flow and amniotic fluid volume.
authors.affiliation: Department of Obstetrics and Gynecology, David-Geffen School of Medicine at University of California Los Angeles, Harbor-University of California Los Angeles Medical Center, Torrance, CA 90502, USA. mdesai@obgyn.humc.edu
authors.forename: Mina
authors.initials: M
authors.lastname: Desai
authors.forename: Zhice
authors.initials: Z
authors.lastname: Xu
authors.forename: Catalina
authors.initials: C
authors.lastname: Guerra
authors.forename: Nathash
authors.initials: N
authors.lastname: Kallichanda
authors.forename: Michael G
authors.initials: MG
authors.lastname: Ross
mesh_terms: D000208:Acute Disease; D000818:Animals; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology*; D004231:Diuresis / Q000187:drug effects; D005260:Female; D005315:Fetal Diseases / Q000097:blood / Q000503:physiopathology*; D006400:Hematocrit; D006470:Hemorrhage / Q000097:blood / Q000503:physiopathology*; D007010:Hyponatremia / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology*; D007668:Kidney / Q000187:drug effects / Q000196:embryology; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D034561:Sheep, Domestic; D014867:Water / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D014867:Water; D003894:Deamino Arginine Vasopressin